|Bid price||25.00||Open price||24.00|
|Ask price||25.50||Prev close||25.25|
Register now for FREE live Allergy Therapeutics share prices, Allergy Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Allergy Therapeutics Level 2 Data, indepth research tools and investor commentary for Allergy Therapeutics (AGY) and other London Stock Exchange equities.
Register now for FREE Allergy Therapeutics share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B02LCQ05|
|Activites||Allergy Therapeutics plc is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of Â£42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging markets.||Index||n/a|
|Latest Share Price (p)||25.25||Net Gearing (%)||5.20|
|Market Capitalisation (£m)||142.43||Gross Gearing (%)||46.50|
|Shares in issue (m)||593.44||Debt Ratio||31.33|
|P/E Ratio||-10.48||Debt-to-Equity Ratio||0.53|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.87|
|Dividend Yield (%)||0.00||Price to book value||4.70|
|Dividend cover (x)||0.00||ROCE (%)||-27.31|
|Earning per share (p)||-2.29||EPS Growth (%)||-11,550.00|
|52 week high / low||28.38 / 16.38||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
RNS Number : 6686U Allergy Therapeutics PLC 20 January 2017 Hardman Research: Investment driving market share gains Investment driving market share gains : AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro...
finnCap today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 43p (from 40p). Story provided by StockMarketWire.com
Allergy Therapeutics expects reported revenues for the six months ended 31 December to be £40.4m - representing 17.9% organic growth at constant currency and 39.3% growth on a reported basis, aided by the impact on euro revenues of the weak pound. The group said this growth reflected continued...
Register now for FREE Allergy Therapeutics company news
Mission Statement To create a sustainable, fast-growing and profitable global speciality pharmaceutical business with a substantial franchise in the allergy sector by developing innovative, patented, registered therapies for both the treatment and prevention of allergy-related conditions....
Good morning, Below is a short TV interview with Manuel & Ian covering today's interim results. www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/
Register now for FREE Allergy Therapeutics share price discussions